Page last updated: 2024-11-05

thalidomide and Neoplasm Metastasis

thalidomide has been researched along with Neoplasm Metastasis in 65 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Research Excerpts

ExcerptRelevanceReference
"This study aimed to assess the efficacy and safety of combination treatment with lenalidomide and cetuximab in KRAS-mutant metastatic colorectal cancer patients."9.17Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. ( Beck, R; Bencardino, K; Elez, ME; Gandhi, A; Jungnelius, U; Li, M; Prenen, H; Romano, A; Sanchis, M; Sartore-Bianchi, A; Shi, T; Siena, S; Tabernero, J; Tejpar, S; Van Cutsem, E, 2013)
"This phase I trial assessed the maximal tolerated dose (MTD) of dacarbazine in combination with lenalidomide in metastatic melanoma."9.14Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. ( Bassett, R; Bedikian, A; Hwu, P; Hwu, WJ; Kim, KB; Knight, RD; Papadopoulos, NE; Patnana, M, 2010)
"This phase II study evaluated the efficacy and tolerability of dacarbazine in combination with thalidomide in metastatic melanoma patients."9.14Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. ( Chang, JL; Farrell, K; Jones, A; Muggia, F; Oratz, R; Ott, PA; Pavlick, AC, 2009)
" The higher dose of lenalidomide did not improve response rate, time to progression, or OS of patients with relapsed/refractory stage IV melanoma."9.14Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. ( Agarwala, SS; Atkins, MB; Bedikian, AY; Glaspy, J; Jungnelius, JU; Knight, RD; O'Day, S; Richards, JM, 2009)
"The results of an international, multicenter, randomized, double-blind, controlled study assessing the efficacy and safety of lenalidomide treatment in patients with refractory stage IV metastatic malignant melanoma are reported."9.14Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. ( Eisen, T; Glaspy, J; Hamilton, A; Hersey, P; Jungnelius, JU; Knight, RD; Millward, M; Trefzer, U, 2010)
"In limited institution phase 2 studies, thalidomide and temozolomide has yielded response rates (RRs) up to 32% for advanced melanoma, leading to the use of this combination as "standard" by some."9.14Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. ( Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA, 2010)
"We examined the toxicity/efficacy of capecitabine with thalidomide, administered over 21-day cycles, in 24 previously treated metastatic breast cancer (MBC) patients."9.14Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer. ( Barton, JH; Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Meluch, AA; Shipley, D; Yardley, DA, 2010)
"Southwest Oncology Group protocol 0026 evaluated interferon alpha-2b plus thalidomide in patients with disseminated melanoma."9.12Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. ( Clark, JI; Flaherty, LE; Hutchins, LF; Lange, MK; Moon, J; Sondak, VK; Thompson, JA, 2007)
"This phase II study evaluated the combination of semaxanib, a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor-2, and thalidomide in patients with metastatic melanoma to assess the efficacy, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the combination."9.12A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ( Beeram, M; Berg, K; de Bono, JS; Eckhart, SG; Forero, L; Hammond, LA; Izbicka, E; Mita, AC; Mita, MM; Patnaik, A; Rowinsky, EK; Simmons, P; Takimoto, C; Tolcher, AW; Weiss, GR, 2007)
"We previously demonstrated efficacy and impact on serum vascular endothelial growth factor (VEGF) for metronomic cyclophosphamide (C) and methotrexate (M) in patients with breast cancer."9.12Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. ( Colleoni, M; Ghisini, R; Goldhirsch, A; Maisonneuve, P; Nolè, F; Orlando, L; Peruzzotti, G; Rocca, A; Sandri, MT; Sanna, G; Viale, G; Zorzino, L, 2006)
"One hundred eighty-one patients with metastatic melanoma were randomly assigned to receive up to six 4-weekly cycles consisting of temozolomide 200 mg/m2 every 8 hours for five doses, or temozolomide 200 mg/m2 daily for days 1 to 5 plus interferon alfa-2b 5 MU (million International Units) subcutaneously three times a week, or temozolomide 150 mg/m2 (increased after one cycle to 200 mg/m2) daily on days 1 to 5 plus thalidomide 100 mg daily days 1 to 28."9.10Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003)
"Single-agent thalidomide has little or no activity in patients with heavily pretreated breast cancer."9.09Phase II evaluation of thalidomide in patients with metastatic breast cancer. ( Baidas, SM; Crawford, JG; Fleming, GF; Flockhart, D; Hanfelt, J; Harris, L; Hawkins, MJ; Hayes, DF; Isaacs, C; Johnson, MD; Lippman, ME; Pluda, JM; Tefft, M; Winer, EP; Yamauchi, H, 2000)
"Fifteen patients with metastatic colorectal cancer were treated with irinotecan (CPT-11, Camptosar) at 300 to 350 mg/m2 every 21 days and thalidomide (Thalomid) at 400 mg/d."9.09Irinotecan and thalidomide in metastatic colorectal cancer. ( Govindarajan, R, 2000)
"Thalidomide can significantly inhibit angiogenesis and metastasis of hepatocellular carcinoma."7.73Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. ( Liu, ZS; Sun, Q; Zhang, ZL, 2005)
"Thalidomide+IFN is a safe and tolerable palliative treatment for previously treated stage IV melanoma."6.73A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. ( Berd, D; Mastrangelo, MJ; Sato, T; Solti, M, 2007)
"Thalidomide was escalated individually to 600 mg po QD as tolerated."6.72The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B, 2006)
"Although melanoma is a relatively chemoresistant malignancy, systemic chemotherapy remains the primary treatment for metastatic melanoma."6.41New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. ( Hwu, WJ, 2000)
"Patients with metastatic colorectal cancer are receiving 350 mg/m2 of irinotecan every 3 weeks plus 400 mg/m2/d of thalidomide."6.41Irinotecan/thalidomide in metastatic colorectal cancer. ( Govindarajan, R, 2002)
"Lenalidomide is an oral drug with immune-modulatory and anti-angiogenic activity against selected hematologic malignancies but as yet little is known regarding its effectiveness for solid tumors."5.43Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. ( Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L, 2016)
"Thalidomide has recently been shown to antagonize basic fibroblast growth factor-induced angiogenesis in the rat corneal micropocket assay."5.29The effect of thalidomide on experimental tumors and metastases. ( Clow, KA; Fryer, KH; Hayes, MM; Minchinton, AI; Wendt, KR, 1996)
"This study aimed to assess the efficacy and safety of combination treatment with lenalidomide and cetuximab in KRAS-mutant metastatic colorectal cancer patients."5.17Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. ( Beck, R; Bencardino, K; Elez, ME; Gandhi, A; Jungnelius, U; Li, M; Prenen, H; Romano, A; Sanchis, M; Sartore-Bianchi, A; Shi, T; Siena, S; Tabernero, J; Tejpar, S; Van Cutsem, E, 2013)
" The higher dose of lenalidomide did not improve response rate, time to progression, or OS of patients with relapsed/refractory stage IV melanoma."5.14Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. ( Agarwala, SS; Atkins, MB; Bedikian, AY; Glaspy, J; Jungnelius, JU; Knight, RD; O'Day, S; Richards, JM, 2009)
"The results of an international, multicenter, randomized, double-blind, controlled study assessing the efficacy and safety of lenalidomide treatment in patients with refractory stage IV metastatic malignant melanoma are reported."5.14Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. ( Eisen, T; Glaspy, J; Hamilton, A; Hersey, P; Jungnelius, JU; Knight, RD; Millward, M; Trefzer, U, 2010)
"In limited institution phase 2 studies, thalidomide and temozolomide has yielded response rates (RRs) up to 32% for advanced melanoma, leading to the use of this combination as "standard" by some."5.14Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. ( Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA, 2010)
"We examined the toxicity/efficacy of capecitabine with thalidomide, administered over 21-day cycles, in 24 previously treated metastatic breast cancer (MBC) patients."5.14Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer. ( Barton, JH; Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Meluch, AA; Shipley, D; Yardley, DA, 2010)
"This phase II study evaluated the efficacy and tolerability of dacarbazine in combination with thalidomide in metastatic melanoma patients."5.14Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. ( Chang, JL; Farrell, K; Jones, A; Muggia, F; Oratz, R; Ott, PA; Pavlick, AC, 2009)
"This phase I trial assessed the maximal tolerated dose (MTD) of dacarbazine in combination with lenalidomide in metastatic melanoma."5.14Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. ( Bassett, R; Bedikian, A; Hwu, P; Hwu, WJ; Kim, KB; Knight, RD; Papadopoulos, NE; Patnana, M, 2010)
"The purpose of the study was to evaluate the efficacy and safety of a bone-targeted regimen consisting of zoledronate, thalidomide, and interferon-gamma in patients with renal cell carcinoma and bone metastases."5.12Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. ( Do, KA; Jonasch, E; Lin, P; Lin, SH; Mathew, P; Pagliaro, LC; Rhines, L; Siefker-Radtke, A; Tannir, N; Tibbs, R; Tu, SM, 2006)
"Southwest Oncology Group protocol 0026 evaluated interferon alpha-2b plus thalidomide in patients with disseminated melanoma."5.12Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. ( Clark, JI; Flaherty, LE; Hutchins, LF; Lange, MK; Moon, J; Sondak, VK; Thompson, JA, 2007)
"This phase II study evaluated the combination of semaxanib, a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor-2, and thalidomide in patients with metastatic melanoma to assess the efficacy, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the combination."5.12A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ( Beeram, M; Berg, K; de Bono, JS; Eckhart, SG; Forero, L; Hammond, LA; Izbicka, E; Mita, AC; Mita, MM; Patnaik, A; Rowinsky, EK; Simmons, P; Takimoto, C; Tolcher, AW; Weiss, GR, 2007)
"We previously demonstrated efficacy and impact on serum vascular endothelial growth factor (VEGF) for metronomic cyclophosphamide (C) and methotrexate (M) in patients with breast cancer."5.12Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. ( Colleoni, M; Ghisini, R; Goldhirsch, A; Maisonneuve, P; Nolè, F; Orlando, L; Peruzzotti, G; Rocca, A; Sandri, MT; Sanna, G; Viale, G; Zorzino, L, 2006)
"One hundred eighty-one patients with metastatic melanoma were randomly assigned to receive up to six 4-weekly cycles consisting of temozolomide 200 mg/m2 every 8 hours for five doses, or temozolomide 200 mg/m2 daily for days 1 to 5 plus interferon alfa-2b 5 MU (million International Units) subcutaneously three times a week, or temozolomide 150 mg/m2 (increased after one cycle to 200 mg/m2) daily on days 1 to 5 plus thalidomide 100 mg daily days 1 to 28."5.10Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003)
"Single-agent thalidomide has little or no activity in patients with heavily pretreated breast cancer."5.09Phase II evaluation of thalidomide in patients with metastatic breast cancer. ( Baidas, SM; Crawford, JG; Fleming, GF; Flockhart, D; Hanfelt, J; Harris, L; Hawkins, MJ; Hayes, DF; Isaacs, C; Johnson, MD; Lippman, ME; Pluda, JM; Tefft, M; Winer, EP; Yamauchi, H, 2000)
"Fifteen patients with metastatic colorectal cancer were treated with irinotecan (CPT-11, Camptosar) at 300 to 350 mg/m2 every 21 days and thalidomide (Thalomid) at 400 mg/d."5.09Irinotecan and thalidomide in metastatic colorectal cancer. ( Govindarajan, R, 2000)
"Thalidomide can significantly inhibit angiogenesis and metastasis of hepatocellular carcinoma."3.73Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. ( Liu, ZS; Sun, Q; Zhang, ZL, 2005)
"Twenty-six patients with advanced cancer (14 men/12 women), median age of 56 years (range 38-70 years), and a median number of two prior therapies (range 0-12) were enrolled."2.80Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. ( Abdelrahim, M; Bilen, MA; Erguvan-Dogan, B; Falchook, GS; Fu, S; Hong, DS; Kurzrock, R; Naing, A; Ng, CS; Tsimberidou, AM; Wheler, JJ, 2015)
"To evaluate the 6-mo overall survival, safety and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer."2.78Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial. ( Arkenau, HT; Bendell, JC; Burris, HA; Hainsworth, JD; Infante, JR; Jones, GT; Lane, CM; Rubin, MS; Spigel, DR; Waterhouse, D, 2013)
" Intermittent dosing of pomalidomide allowed substantially higher doses than were previously reported with a continuous schedule."2.76A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer. ( Bendell, JC; Burris, HA; Hainsworth, JD; Infante, JR; Jones, SF; Messersmith, WA; Spigel, DR; Weekes, CD; Yardley, DA, 2011)
" Lenalidomide was well tolerated up to a 35-mg/d intermittent dosing schedule at doses higher than previously indicated for hematologic malignancies."2.74Phase I study of oral lenalidomide in patients with refractory metastatic cancer. ( Aragon-Ching, JB; Arlen, PM; Dahut, WL; Figg, WD; Gulley, JL; Tohnya, TM; Ventiz, J; Woo, S; Wright, JJ, 2009)
"Thalidomide was fairly well tolerated in patients with metastatic carcinoid/islet cell tumors, but failed to reveal any objective responses."2.73Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. ( Campbell, J; Shah, MH; Varker, KA, 2008)
"Thalidomide+IFN is a safe and tolerable palliative treatment for previously treated stage IV melanoma."2.73A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. ( Berd, D; Mastrangelo, MJ; Sato, T; Solti, M, 2007)
"Gemcitabine was given by intravenous administration over 30 min on day 1, week 1 and day 8, week 2."2.73A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma. ( Amato, RJ; Khan, M, 2008)
"Fourteen patients with metastatic renal cell carcinoma (RCC) were enrolled on a phase 2 trial of lenalidomide administered orally at 25 mg daily for 21 days followed by a rest period of 7 days."2.73Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. ( Bacik, J; DeLuca, J; Ishill, N; Kondagunta, GV; Motzer, RJ; Patel, PH; Russo, P; Schwartz, L, 2008)
"Thalidomide 100 mg was kept stable for all cohorts."2.73A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. ( Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS, 2007)
"Thalidomide was escalated individually to 600 mg po QD as tolerated."2.72The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B, 2006)
"Disease progression was observed in 24 patients (47%)."2.72Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. ( Amato, RJ; Morgan, M; Rawat, A, 2006)
" Pharmacokinetic data suggested a decreased metabolism of irinotecan into SN-38 and SN-38-glucuronide when it was administered with thalidomide."2.72Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. ( Allegrini, G; Amatori, F; Bocci, G; Cerri, E; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Marcucci, L; Masi, G, 2006)
"Lenalidomide (LEN) is a structural and functional analogue of thalidomide that has demonstrated enhanced immunomodulatory properties and a more favorable toxicity profile."2.72Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. ( Baz, RC; Bukowski, RM; Choueiri, TK; Dreicer, R; Elson, P; Garcia, JA; Jinks, HA; Mekhail, TM; Rini, BI; Thakkar, SG, 2006)
"The treatment of advanced renal cell cancer remains unsatisfactory, therefore new combination regimens such as thalidomide and IL-2 are of interest."2.72Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma. ( Bukowski, RM; Dreicer, R; Elson, P; Malhi, S; Mekhail, T; Olencki, T; Wood, L, 2006)
"Oral thalidomide was started at 200 mg/day and escalated after 2 days to 400 mg/day at week 0."2.71Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma. ( Hegele, A; Heidenreich, A; Hofmann, R; Ohlmann, CH; Olbert, P; Schrader, AJ; Varga, Z; von Knobloch, R, 2005)
"Thalidomide was first given 100 mg/d for 1 week and 300 mg/d thereafter."2.71Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. ( Ahtinen, H; Bono, P; Hernberg, M; joensuu, H; Mäenpää, H; Virkkunen, P, 2003)
"The highly vascular nature of renal cell carcinoma (RCC) suggests that angiogenesis inhibition may be therapeutic for patients with this disease."2.70A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. ( Amato, R; Daliani, DD; Oliva, R; Pagliaro, L; Papandreou, CN; Perez, C; Thall, PF; Wang, X, 2002)
"Thalidomide was discontinued in 55 patients for lack of therapeutic response."2.70Thalidomide neuropathy in patients treated for metastatic prostate cancer. ( Culcea, E; Dahut, W; Figg, WD; Floeter, MK; Kruger, EA; Molloy, FM; Pluda, J; Reed, E; Sandbrink, F; Steinberg, SM; Syed, NA, 2001)
"Recent advances in the treatment of multiple myeloma have resulted in improved response rates and overall survival in patients with multiple myeloma."2.46Advances in treatment for relapses and refractory multiple myeloma. ( Richards, T; Weber, D, 2010)
"Germ cell tumors are the most common malignancies in men under 50 years and also the most common cause of death from solid tumors in this age group."2.45Germ cell tumors of the gonads: a selective review emphasizing problems in drug resistance and current therapy options. ( Albers, P; Christoph, F; Hinz, S; Hoepfner, M; Jung, K; Kempkensteffen, C; Krause, H; Lein, M; Miller, K; Schostak, M; Schrader, M; Stephan, C; Weikert, S, 2009)
"Thalidomide has significant neurotoxicity and its efficacy was not confirmed in recent studies."2.42Renal cell carcinoma: novel treatments for advanced disease. ( Heinzer, H; Huland, E, 2003)
"Several promising approaches to the treatment of renal cancer have been developed over recent years."2.41[Metastatic kidney cancer: new therapeutic approaches]. ( Escudier, B; Mejean, A; Negrier, S; Oudard, S, 2002)
"Although melanoma is a relatively chemoresistant malignancy, systemic chemotherapy remains the primary treatment for metastatic melanoma."2.41New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. ( Hwu, WJ, 2000)
"Thalidomide, which was developed as a nonbarbiturate sedative agent, was taken off the market in 1961 after it was linked to a spate of major birth defects."2.41Thalidomide: new indications? ( Combe, B, 2001)
"Patients with metastatic colorectal cancer are receiving 350 mg/m2 of irinotecan every 3 weeks plus 400 mg/m2/d of thalidomide."2.41Irinotecan/thalidomide in metastatic colorectal cancer. ( Govindarajan, R, 2002)
"Lenalidomide is an oral drug with immune-modulatory and anti-angiogenic activity against selected hematologic malignancies but as yet little is known regarding its effectiveness for solid tumors."1.43Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. ( Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L, 2016)
"In addition, an in vivo experimental metastasis model also showed that treatment with the drugs resulted in a significantly lower number of metastatic pulmonary nodules relative to control mice."1.35Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). ( Bartlett, JB; Dalgleish, AG; Galustian, C; Henry, JY; Liu, WM; Meyer, B, 2009)
"Oral thalidomide was started at 200 mg/d and escalated after two days to 400 mg/d at week 0."1.33[Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study]. ( Hegele, A; Heidenreich, A; Hofmann, R; Olbert, P; Schrader, AJ; Varga, Z, 2006)
"Thalidomide has demonstrated clinical activity in various malignancies including androgen-independent prostate cancer."1.32Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. ( Eger, K; Figg, WD; Gütschow, M; MacPherson, GR; Ng, SS, 2004)
"Thalidomide has recently been shown to antagonize basic fibroblast growth factor-induced angiogenesis in the rat corneal micropocket assay."1.29The effect of thalidomide on experimental tumors and metastases. ( Clow, KA; Fryer, KH; Hayes, MM; Minchinton, AI; Wendt, KR, 1996)

Research

Studies (65)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (4.62)18.2507
2000's45 (69.23)29.6817
2010's17 (26.15)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sundaresan, L1
Kumar, P1
Chatterjee, S1
Prince, SK1
Forgeson, G1
Siena, S1
Van Cutsem, E1
Li, M1
Jungnelius, U1
Romano, A1
Beck, R1
Bencardino, K1
Elez, ME1
Prenen, H1
Sanchis, M1
Sartore-Bianchi, A1
Tejpar, S1
Gandhi, A1
Shi, T1
Tabernero, J1
Broccoli, A1
Pellegrini, C1
Celli, M1
Argnani, L1
Agostinelli, C1
Pileri, S1
Zinzani, PL1
Agarwal, N1
Apolo, AB1
Tsao, CK1
Lee, KM1
Godbold, JH1
Soto, R1
Poole, A1
Gimpel-Tetra, K1
Lowe, N1
Oh, WK1
Galsky, MD1
Bilen, MA1
Fu, S1
Falchook, GS1
Ng, CS1
Wheler, JJ1
Abdelrahim, M1
Erguvan-Dogan, B1
Hong, DS1
Tsimberidou, AM1
Kurzrock, R1
Naing, A1
Leuci, V1
Maione, F1
Rotolo, R1
Giraudo, E1
Sassi, F1
Migliardi, G1
Todorovic, M1
Gammaitoni, L1
Mesiano, G1
Giraudo, L1
Luraghi, P1
Leone, F1
Bussolino, F1
Grignani, G1
Aglietta, M1
Trusolino, L1
Bertotti, A1
Sangiolo, D1
Lu, L1
Payvandi, F1
Wu, L1
Zhang, LH1
Hariri, RJ1
Man, HW1
Chen, RS1
Muller, GW1
Hughes, CC1
Stirling, DI1
Schafer, PH1
Bartlett, JB2
Schrader, M1
Kempkensteffen, C1
Christoph, F1
Hinz, S1
Weikert, S1
Lein, M1
Krause, H1
Stephan, C1
Jung, K1
Hoepfner, M1
Albers, P1
Miller, K1
Schostak, M1
Dahut, WL3
Aragon-Ching, JB1
Woo, S1
Tohnya, TM2
Gulley, JL2
Arlen, PM2
Wright, JJ2
Ventiz, J1
Figg, WD5
Ott, PA1
Chang, JL1
Oratz, R1
Jones, A1
Farrell, K1
Muggia, F1
Pavlick, AC1
Liu, WM1
Henry, JY1
Meyer, B1
Dalgleish, AG1
Galustian, C1
Ning, YM1
Glaspy, J2
Atkins, MB1
Richards, JM1
Agarwala, SS1
O'Day, S1
Knight, RD3
Jungnelius, JU2
Bedikian, AY1
Eisen, T1
Trefzer, U1
Hamilton, A1
Hersey, P1
Millward, M1
Clark, JI2
Moon, J2
Hutchins, LF2
Sosman, JA1
Kast, WM1
Da Silva, DM1
Liu, PY1
Thompson, JA2
Flaherty, LE2
Sondak, VK2
Burris, HA3
Jones, SF2
Shipley, D1
Meluch, AA1
Greco, FA1
Barton, JH1
Yardley, DA2
Hainsworth, JD3
Richards, T1
Weber, D1
Hwu, WJ2
Patnana, M1
Bassett, R1
Papadopoulos, NE1
Kim, KB1
Hwu, P1
Bedikian, A1
Infante, JR2
Bendell, JC2
Spigel, DR2
Weekes, CD1
Messersmith, WA1
Shenoy, SK1
Han, S1
Zhao, YL1
Hara, MR1
Oliver, T1
Cao, Y1
Dewhirst, MW1
Park, B1
Sung, B1
Yadav, VR1
Chaturvedi, MM1
Aggarwal, BB1
Shukla, N1
Kobos, R1
Renaud, T1
Teruya-Feldstein, J1
Price, A1
McAllister-Lucas, L1
Steinherz, P1
Arkenau, HT1
Rubin, MS1
Waterhouse, D1
Jones, GT1
Lane, CM1
Daliani, DD1
Papandreou, CN1
Thall, PF1
Wang, X1
Perez, C1
Oliva, R1
Pagliaro, L1
Amato, R2
Negrier, S1
Mejean, A1
Oudard, S1
Escudier, B1
Mall, JW1
Philipp, AW1
Mall, W1
Pollmann, C1
Danson, S1
Lorigan, P1
Arance, A1
Clamp, A1
Ranson, M1
Hodgetts, J1
Lomax, L1
Ashcroft, L1
Thatcher, N1
Middleton, MR1
Hernberg, M1
Virkkunen, P1
Bono, P1
Ahtinen, H1
Mäenpää, H1
joensuu, H1
Huland, E1
Heinzer, H1
Sparano, JA1
Gray, R1
Giantonio, B1
O'Dwyer, P1
Comis, RL1
Gulley, J1
Dahut, W2
Ng, SS2
Parker, C1
Zeldis, J1
MacPherson, GR1
Gütschow, M1
Eger, K1
Zhang, ZL1
Liu, ZS1
Sun, Q1
Schrader, AJ2
Heidenreich, A2
Hegele, A2
Olbert, P2
Ohlmann, CH1
Varga, Z2
von Knobloch, R1
Hofmann, R2
Colleoni, M2
Orlando, L1
Sanna, G1
Rocca, A2
Maisonneuve, P2
Peruzzotti, G2
Ghisini, R1
Sandri, MT2
Zorzino, L2
Nolè, F1
Viale, G1
Goldhirsch, A1
McCollum, AD1
Wu, B1
Clark, JW1
Kulke, MH1
Enzinger, PC1
Ryan, DP1
Earle, CC1
Michelini, A1
Fuchs, CS1
Amato, RJ3
Morgan, M1
Rawat, A1
Allegrini, G1
Di Paolo, A1
Cerri, E1
Cupini, S1
Amatori, F1
Masi, G1
Danesi, R1
Marcucci, L1
Bocci, G1
Del Tacca, M1
Falcone, A1
Olencki, T1
Malhi, S1
Mekhail, T1
Dreicer, R2
Elson, P2
Wood, L1
Bukowski, RM2
Mita, MM1
Rowinsky, EK1
Forero, L1
Eckhart, SG1
Izbicka, E1
Weiss, GR1
Beeram, M1
Mita, AC1
de Bono, JS1
Tolcher, AW1
Hammond, LA1
Simmons, P1
Berg, K1
Takimoto, C1
Patnaik, A1
Rick, O1
Braun, T1
Siegert, W1
Beyer, J1
Tannir, N1
Jonasch, E1
Pagliaro, LC1
Mathew, P1
Siefker-Radtke, A1
Rhines, L1
Lin, P1
Tibbs, R1
Do, KA1
Lin, SH1
Tu, SM1
Alikunju, S1
Pillarisetti, S1
Choueiri, TK1
Rini, BI1
Garcia, JA1
Thakkar, SG1
Baz, RC1
Mekhail, TM1
Jinks, HA1
Johansson, HA1
Salvatici, M1
Passerini, R1
Laber, DA1
Khan, MI1
Kloecker, GH1
Schonard, C1
Taft, BS1
Salvador, C1
Varker, KA1
Campbell, J1
Shah, MH1
Solti, M1
Berd, D1
Mastrangelo, MJ1
Sato, T1
Khan, M1
Lange, MK1
Patel, PH1
Kondagunta, GV1
Schwartz, L1
Ishill, N1
Bacik, J1
DeLuca, J1
Russo, P1
Motzer, RJ1
Mohammad, T1
Minchinton, AI1
Fryer, KH1
Wendt, KR1
Clow, KA1
Hayes, MM1
Ono, M1
Kuwano, M1
Bruera, E1
Neumann, CM1
Pituskin, E1
Calder, K1
Ball, G1
Hanson, J1
Baidas, SM1
Winer, EP1
Fleming, GF1
Harris, L1
Pluda, JM1
Crawford, JG1
Yamauchi, H1
Isaacs, C1
Hanfelt, J1
Tefft, M1
Flockhart, D1
Johnson, MD1
Hawkins, MJ1
Lippman, ME1
Hayes, DF1
Govindarajan, R2
Molloy, FM1
Floeter, MK1
Syed, NA1
Sandbrink, F1
Culcea, E1
Steinberg, SM1
Pluda, J1
Kruger, EA1
Reed, E1
Combe, B1

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Open-Label Study To Evaluate The Efficacy And Safety Of Lenalidomide In Combination With Cetuximab In Pretreated Subjects With K-Ras Mutant Metastatic Colorectal Cancer[NCT01032291]Phase 251 participants (Actual)Interventional2009-12-31Terminated (stopped due to A business decision not to continue with Phase 2b based on non-safety observations during proof of concept phase.)
Multi-Center Phase Ib/II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma[NCT01342172]Phase 1/Phase 29 participants (Actual)Interventional2011-03-31Terminated (stopped due to low accrual)
A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy[NCT02018523]Phase 17 participants (Actual)Interventional2014-06-30Terminated (stopped due to Study did not enroll enough subjects to make a statistically sound conclusion.)
A Multidose Phase I Study of Oral CC5013, a Thalidomide Derivative, in Patients With Refractory Metastatic Cancer[NCT00031941]Phase 10 participants Interventional2002-04-30Completed
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2, or IFN Based Therapy[NCT00057616]Phase 3274 participants Interventional2002-10-01Completed
A Phase II Trial of Combination Thalidomide Plus Temozolomide in Patients With Metastatic Malignant Melanoma[NCT00104988]Phase 264 participants (Actual)Interventional2005-06-30Completed
Phase II Study of Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer[NCT00193102]Phase 240 participants (Anticipated)Interventional2001-04-30Terminated
Phase I Safety Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy[NCT00179608]Phase 128 participants Interventional2005-09-01Completed
A Phase I/II Study of CC-4047 in Combination With Gemcitabine in Subjects With Untreated Advanced Carcinoma of the Pancreas[NCT00540579]Phase 1/Phase 223 participants (Actual)Interventional2007-11-30Completed
Evaluation of Interferon Alpha-2b and Thalidomide in Patients With Disseminated Malignant Melanoma, Phase II[NCT00026520]Phase 20 participants Interventional2001-11-30Completed
Phase II Trial of CC-5013 in Patients With Advanced Renal Cell Carcinoma With Either No Prior Treatment or One Prior Treatment Regimen[NCT00096525]Phase 20 participants Interventional2004-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Participants With Dose Limiting Toxicities (DLTs) During the First Treatment Cycle of the Safety Lead-In Period

"The number of participants with DLTs determines the maximum tolerated dose of the combination therapy used in the Proof of Concept (POC) period:~If <2 of the initial 6 participants experience a DLT, then the POC will start with lenalidomide at 25 mg.~If ≥2 of the initial 6 participants experienced a DLT, then 6 more subjects were to be enrolled at 20 mg lenalidomide.~If <2 of the additional 6 subjects experienced a DLT, then the lenalidomide starting dose for the POC was to be 20 mg.~If ≥2 of the additional 6 subjects experienced a DLT, then 6 more subjects were to be enrolled at 15 mg lenalidomide.~If <2 of the additional 6 subjects experienced a DLT, then the POC was to start with lenalidomide at 15 mg.~If ≥2 of the additional 6 subjects experienced a DLT, the dosing for the study was to be reassessed by Celgene Corporation and the investigators." (NCT01032291)
Timeframe: Up to Day 28 (Cycle 1)

Interventionparticipants (Number)
Lenalidomide Plus Cetuximab (Safety Lead-in)1

Best Overall Response Assessed by an Independent Review Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) During the Proof of Concept Period Prior to Early Study Termination

"Tumor response was evaluated every 2 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response and progression were evaluated using the RECIST 1.1 criteria (Eisenhauer, 2009).~Complete response-disappearance of all lesions~Partial response-30% decrease in the sum of diameters of target lesions from baseline~Stable disease-neither shrinkage nor increase of lesions.~Progressive Disease-20% increase in the sum of diameters of target lesions from nadir.~Participants with evidence of objective tumor response have the response confirmed with repeat assessments performed at the next scheduled scan." (NCT01032291)
Timeframe: Week 9 up to week 24

,
Interventionparticipants (Number)
Complete ResponsePartial ResponseStable DiseaseProgressive DiseaseResponse Not Evaluable
Lenalidomide (Proof of Concept)003135
Lenalidomide Plus Cetuximab (Proof of Concept)005133

Participants With Treatment-Emergent Adverse Events (TEAE)

TEAEs are any adverse event occurring or worsening on or after the first treatment of any study drug and within 28 days after the last dose of the last study drug received. Relation to study drug was determined by the investigator. Severity of AE is graded according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.0. Severity is a 5-point scale: 3= severe or medically significant but not life-threatening 4=life-threatening, urgent intervention required 5=death related to AE. (NCT01032291)
Timeframe: up to week 28

,,
Interventionparticipants (Number)
>=1 TEAESerious TEAETEAE leading to discontinuing lenalidomideTEAE leading to discontinuing cetuximabTEAE leading to reduction/interruption of lenalidoTEAE leading to reduction/interruption of cetuximaTEAE related to lenalidomideTEAE related to cetuximabTEAE NCI CTC grade 3 or higherTEAE NCI CTC grade 3+ related to lenalidomideTEAE NCI CTC grade 3+ related to cetuximabSerious TEAE related to lenalidomideSerious TEAE related to cetuximab
Lenalidomide (Proof of Concept)2097NA6NA9NA134NA0NA
Lenalidomide Plus Cetuximab (Proof of Concept)21956971319124722
Lenalidomide Plus Cetuximab (Safety Lead-In)8533215843222

Maximum Tolerated Dose (MTD) of Lenalidomide

MTD was determined by testing planned increasing doses up to 25 mg daily dose on days 1-14, starting at 10mg. MTD reflects the highest dose of drug that did not cause a Dose-Limiting Toxicity (DLT) in > 33% of participants. DLTs were defined as any lenalidomide-related Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE 4.0) Grade 3 or 4 adverse events (NCT01342172)
Timeframe: after 1 cycle (each cycle is 21 days)

Interventionmg (Number)
Lenalidomide10

Best Overall Response

"Best Overall Response to evaluate lenalidomide as maintenance treatment in patients achieving an objective response of either complete response or partial response following completion of 6 cycles of combination therapy.~Complete Response (CR) - CR of target lesions and no new lesions Partial Response (PR) -PR of target lesions and no new lesions Stable Disease (SD) - SD of target lesions and no new lesions Progression Disease (PD) - any status of target lesions and new lesions" (NCT01342172)
Timeframe: 168 days

InterventionParticipants (Count of Participants)
CRPR
Lenalidomide12

Number of Grade >=3 Adverse Events

Number of grade >=3 adverse events to assess the safety of combination therapy with gemcitabine, cisplatin plus lenalidomide as determined by the frequency and severity of adverse events as per the NCI Common Terminology for Adverse Events (CTCAE) version 4.0. (NCT01342172)
Timeframe: Day 1 and Day 8 of each treatment cycle; 21 days after the last dose of Lenalidomide

Interventionevents (Number)
Grade 3Grade 4
Lenalidomide287

The Objective Response Rate to Treatment With Gemcitabine, Cisplatin, Plus Lenalidomide

"The objective response rate as determined by Response Evaluation Criteria in Solid Tumors (RECIST).~Complete Response (CR) Disappearance of all target lesions for a period of at least one month.~Partial Response (PR) At least a 30% decrease in the sum of the longest diameter of measures lesions (target lesions), taking as reference the baseline sum of the longest diameter.~Stable Disease (NR/SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since the treatment started.~Progressive Disease (PD) A 20% or greater increase in the sum of the longest diameter of measured lesions (target lesions), taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions" (NCT01342172)
Timeframe: After 2 cycles (a cycle is 21 days)

InterventionParticipants (Count of Participants)
CRPRSDPDnot evaluable
Lenalidomide12321

The Safety and Tolerability of Protocol Treatment, Defined as the Percentage of Patients Experiencing Severe or Life-threatening Side Effects Per CTCAE Version 3.0

The relative incidence of Grade 3/4 adverse events from protocol treatment as defined by Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (NCT00540579)
Timeframe: 24 Months

Interventionpercentage of patients (Number)
Pomalidomide/Gemcitabine39

Determination of Maximum Tolerated Dose (MTD), The Dose of Study Drug(s) Which Causes <33% of Patients Treated to Experience Unacceptable Side Effects

"Unacceptable side effects or dose-limiting toxicities (DLTs) were defined as follows:~Inability to Complete cycle 1 of therapy due to drug-related toxicity.~> Grade 3 non-hematological drug-related toxicity (excluding alopecia) despite optimal supportive care~Febrile neutropenia (absolute neutrophil count [ANC] <1,000/μL and fever >101° F (38.5° C))~Grade 4 neutropenia that occurs prior to day 21. (Grade 4 neutropenia that occurs after day 21 but resolves within 7 days of the scheduled cycle 2, will not be considered DLT)~Platelet count < 25,000/μL~Inability to initiate Cycle 2, Day 1 therapy within 7 days of scheduled start (i.e. cannot delay the start of Cycle 2 by more than 7 days following the normal 7 day recovery period) due to drug-related toxicity." (NCT00540579)
Timeframe: 6 months

Interventionmilligrams (Number)
PomalidomideGemcitabine
Pomalidomide/Gemcitabine101000

Reviews

10 reviews available for thalidomide and Neoplasm Metastasis

ArticleYear
Germ cell tumors of the gonads: a selective review emphasizing problems in drug resistance and current therapy options.
    Oncology, 2009, Volume: 76, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell

2009
Advances in treatment for relapses and refractory multiple myeloma.
    Medical oncology (Northwood, London, England), 2010, Volume: 27 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma;

2010
[Metastatic kidney cancer: new therapeutic approaches].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2002, Volume: 12, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Kidney Neoplasms; Neoplasm Metastasis; Neopl

2002
Renal cell carcinoma: novel treatments for advanced disease.
    Current opinion in urology, 2003, Volume: 13, Issue:6

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cancer Vaccines; Carcinoma, Renal Cell; Combined Moda

2003
Novel clinical trials in androgen-independent prostate cancer.
    Clinical prostate cancer, 2002, Volume: 1, Issue:1

    Topics: Androgens; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Cancer Vaccines;

2002
Selected players in the inflammation cascade and drugs that target these inflammation genes against metastasis.
    Anti-cancer agents in medicinal chemistry, 2006, Volume: 6, Issue:5

    Topics: Animals; Anti-Inflammatory Agents; Cytokines; Glucuronidase; Humans; Inflammation; Macrophages; Matr

2006
[Neovascularization and tumor development].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1998, Aug-10, Volume: 87, Issue:8

    Topics: Angiostatins; Antibiotics, Antineoplastic; Antineoplastic Agents; Collagen; Cyclohexanes; Endostatin

1998
New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother

2000
Thalidomide: new indications?
    Joint bone spine, 2001, Volume: 68, Issue:6

    Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Humans; Multiple Myeloma; Neoplasm Metastasis; Neov

2001
Irinotecan/thalidomide in metastatic colorectal cancer.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:4 Suppl 3

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Che

2002

Trials

37 trials available for thalidomide and Neoplasm Metastasis

ArticleYear
Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetu

2013
Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma.
    The oncologist, 2014, Volume: 19, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Drug-Rela

2014
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; L

2015
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
    Journal of clinical pharmacology, 2009, Volume: 49, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Ag

2009
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
    Journal of clinical pharmacology, 2009, Volume: 49, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Ag

2009
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
    Journal of clinical pharmacology, 2009, Volume: 49, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Ag

2009
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
    Journal of clinical pharmacology, 2009, Volume: 49, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Ag

2009
Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Chemotherapy, 2009, Volume: 55, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship

2009
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
    Cancer, 2009, Nov-15, Volume: 115, Issue:22

    Topics: Antineoplastic Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lenalidomi

2009
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
    Cancer, 2010, Jan-01, Volume: 116, Issue:1

    Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female;

2010
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
    Cancer, 2010, Jan-01, Volume: 116, Issue:1

    Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female;

2010
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
    Cancer, 2010, Jan-01, Volume: 116, Issue:1

    Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female;

2010
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
    Cancer, 2010, Jan-01, Volume: 116, Issue:1

    Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female;

2010
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
    Cancer, 2010, Jan-15, Volume: 116, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female;

2010
Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.
    Cancer investigation, 2010, Volume: 28, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy

2010
Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy.
    Melanoma research, 2010, Volume: 20, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dacarbazine; Dose-Respo

2010
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Dru

2011
Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.
    Cancer biology & therapy, 2013, Volume: 14, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea

2013
A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
    Cancer, 2002, Aug-15, Volume: 95, Issue:4

    Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Surv

2002
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jul-01, Volume: 21, Issue:13

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz

2003
Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Oct-15, Volume: 21, Issue:20

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug

2003
A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.
    Clinical prostate cancer, 2004, Volume: 2, Issue:4

    Topics: Administration, Oral; Humans; Lenalidomide; Male; Neoplasm Metastasis; Palliative Care; Prostatic Ne

2004
Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma.
    Anti-cancer drugs, 2005, Volume: 16, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modalit

2005
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2

    Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineo

2006
The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
    American journal of clinical oncology, 2006, Volume: 29, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col

2006
Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
    Cancer, 2006, Apr-01, Volume: 106, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal

2006
Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:5

    Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2006
Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma.
    Investigational new drugs, 2006, Volume: 24, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal

2006
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:2

    Topics: Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Asthenia; Dose-Response Relationship, Drug;

2007
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.
    Cancer, 2006, Aug-01, Volume: 107, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neopla

2006
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
    Cancer, 2006, Dec-01, Volume: 107, Issue:11

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Imm

2006
Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Cancer, 2007, Aug-01, Volume: 110, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cy

2007
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
    Cancer biology & therapy, 2007, Volume: 6, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy

2007
Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:4

    Topics: Adenoma, Islet Cell; Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoid Tumor; Chrom

2008
A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment.
    Melanoma research, 2007, Volume: 17, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progressi

2007
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2008
Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026.
    Cancer, 2007, Nov-15, Volume: 110, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma

2007
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.
    Investigational new drugs, 2008, Volume: 26, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kid

2008
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
    Journal of experimental therapeutics & oncology, 2008, Volume: 7, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Car

2008
Thalidomide in patients with cachexia due to terminal cancer: preliminary report.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:7

    Topics: Aged; Appetite; Cachexia; Female; Humans; Hypnotics and Sedatives; Male; Neoplasm Metastasis; Neopla

1999
Phase II evaluation of thalidomide in patients with metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:14

    Topics: Adult; Aged; Angiogenesis Inhibitors; Breast Neoplasms; Drug Administration Schedule; Endothelial Gr

2000
Irinotecan and thalidomide in metastatic colorectal cancer.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Che

2000
Thalidomide neuropathy in patients treated for metastatic prostate cancer.
    Muscle & nerve, 2001, Volume: 24, Issue:8

    Topics: Action Potentials; Age Factors; Aged; Aged, 80 and over; Brachial Plexus; Cohort Studies; Dose-Respo

2001

Other Studies

18 other studies available for thalidomide and Neoplasm Metastasis

ArticleYear
Mechanistic insights into the differential effects of thalidomide and lenalidomide in metastatic prostate cancer.
    Future oncology (London, England), 2018, Volume: 14, Issue:23

    Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cholesterol; Gene

2018
Bleeding from gastrointestinal tract recurrence of non-seminomatous germ cell tumour testis, showing temporary response to gemcitabine and oxaliplatin chemotherapy.
    The New Zealand medical journal, 2013, Nov-01, Volume: 126, Issue:1385

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gastrointestinal Hemorrhage; G

2013
Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cycl

2014
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.
    Journal of translational medicine, 2016, 05-05, Volume: 14, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce

2016
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
    Microvascular research, 2009, Volume: 77, Issue:2

    Topics: Adherens Junctions; Angiogenesis Inhibitors; Animals; Antigens, CD; Antineoplastic Agents; Basic Hel

2009
Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs).
    British journal of cancer, 2009, Sep-01, Volume: 101, Issue:5

    Topics: Animals; Antineoplastic Agents; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Cytokines;

2009
Reversal of docetaxel resistance with bevacizumab and thalidomide.
    Clinical genitourinary cancer, 2009, Volume: 7, Issue:2

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2009
β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression.
    Oncogene, 2012, Jan-19, Volume: 31, Issue:3

    Topics: Active Transport, Cell Nucleus; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides;

2012
Triptolide, histone acetyltransferase inhibitor, suppresses growth and chemosensitizes leukemic cells through inhibition of gene expression regulated by TNF-TNFR1-TRADD-TRAF2-NIK-TAK1-IKK pathway.
    Biochemical pharmacology, 2011, Nov-01, Volume: 82, Issue:9

    Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Diterpenes; Enzyme Inhibitors; Epoxy Compounds

2011
Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab.
    Cancer, 2012, Aug-01, Volume: 118, Issue:15

    Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Resistance,

2012
Long-term survival of a patient with small-cell lung cancer (SCLC) following treatment with thalidomide and combination chemotherapy.
    Angiogenesis, 2002, Volume: 5, Issue:1-2

    Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Small Cell; Female; Humans; Neoplasm Metastasis; Survivors

2002
Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Feb-15, Volume: 10, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; Co

2004
Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jun-15, Volume: 10, Issue:12 Pt 1

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Humans; Immunoh

2004
Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice.
    World journal of gastroenterology, 2005, Jan-14, Volume: 11, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Division; DNA Prime

2005
Activity of thalidomide in patients with platinum-refractory germ-cell tumours.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:12

    Topics: Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Gonadal Disorders; Humans; Mediastinal Neop

2006
[Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
    Aktuelle Urologie, 2006, Volume: 37, Issue:6

    Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Pro

2006
The effect of thalidomide on experimental tumors and metastases.
    Anti-cancer drugs, 1996, Volume: 7, Issue:3

    Topics: Animals; Combined Modality Therapy; Female; Mice; Neoplasm Metastasis; Neoplasms, Experimental; Neov

1996
Thalidomide for recurrent renal-cell cancer in a 40-year-old man.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1

    Topics: Adenocarcinoma, Clear Cell; Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Therapy, Com

2000